NCT00701766View on ClinicalTrials.gov

BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia

PHASE2CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

October 31, 2009

Conditions
Leukemia, Myeloid, Acute
Interventions
DRUG

BI 2536

Trial Locations (9)

Unknown

1216.20.43001 Boehringer Ingelheim Investigational Site, Innsbruck

1216.20.43002 Boehringer Ingelheim Investigational Site, Vienna

1216.20.49006 Boehringer Ingelheim Investigational Site, Bonn

1216.20.49002 Boehringer Ingelheim Investigational Site, Frankfurt

1216.20.49003 Boehringer Ingelheim Investigational Site, Freiburg im Breisgau

1216.20.49004 Boehringer Ingelheim Investigational Site, Hannover-Heideviertel

1216.20.49007 Boehringer Ingelheim Investigational Site, Heidelberg

1216.20.49005 Boehringer Ingelheim Investigational Site, Münster

1216.20.49001 Boehringer Ingelheim Investigational Site, Ulm

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT00701766 - BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia | Biotech Hunter | Biotech Hunter